Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 2 of 2: GR metrics. - Dataset (ID:20365)

 Full screen view
Filter results: >>>>
Cell line Drug name Experimental replicate Timepoint Curve type (GR values) Curve type (relative cell counts) Experiment name Number of concentrations Cell doublings (DMSO control) GR50 GRmax GR_AOC GEC50 GRinf Hill slope (GR values) R-squared sigmoid fit (GR values) P-value sigmoid fit (GR values) R-squared flat fit (GR values) IC50 Emax AUC EC50 Einf Hill slope (relative cell counts) R-squared sigmoid fit (relative cell counts) P-value sigmoid fit (relative cell counts) R-squared flat fit (relative cell counts)
HCC38 AZD8055 1 72
sigmoid
sigmoid
HCC38 AZD8055 0 1 72
 8 1.773
0.052
0.151
0.479
0.0381
0.136
1.02
0.992
4.28e-07
NA
0.116
0.375
0.633
0.0313
0.363
0.987
0.993
3.89e-07
NA
HCC38 AZD8055 2 72
sigmoid
sigmoid
HCC38 AZD8055 0 2 72
 8 2.128
0.0616
0.16
0.467
0.045
0.124
0.912
0.993
3.13e-07
NA
0.0875
0.314
0.594
0.0332
0.284
0.869
0.991
6.5e-07
NA
HCC38 AZD8055 3 72
sigmoid
sigmoid
HCC38 AZD8055 0 3 72
 8 1.417
0.0464
0.0327
0.53
0.0463
0.000983
1.04
0.997
4.27e-08
NA
0.157
0.392
0.658
0.041
0.372
1.02
0.996
5.78e-08
NA
HCC38 Dactolisib 1 72
sigmoid
sigmoid
HCC38 dactolisib 0 1 72
 8 1.821
0.0109
-0.0403
0.672
0.0104
0.0212
0.892
0.985
3.44e-06
NA
0.0194
0.263
0.492
0.00757
0.301
0.975
0.988
1.65e-06
NA
HCC38 Dactolisib 2 72
sigmoid
sigmoid
HCC38 dactolisib 0 2 72
 8 2.120
0.0118
-0.0557
0.668
0.0118
-0.00134
0.785
0.98
7.61e-06
NA
0.0145
0.204
0.447
0.00701
0.245
0.927
0.988
1.88e-06
NA
HCC38 Dactolisib 3 72
sigmoid
sigmoid
HCC38 dactolisib 0 3 72
 8 1.468
0.0082
-0.197
0.778
0.0127
-0.181
0.711
0.993
3.98e-07
NA
0.0268
0.262
0.497
0.00923
0.277
0.757
0.994
2.62e-07
NA
HCC38 Buparlisib 1 72
sigmoid
sigmoid
HCC38 buparlisib 0 1 72
 8 1.738
0.912
-0.226
0.194
1.46
-0.57
1.62
0.999
9.48e-10
NA
1.2
0.192
0.858
1.12
0.0495
1.66
0.998
4.36e-09
NA
HCC38 Buparlisib 2 72
sigmoid
sigmoid
HCC38 buparlisib 0 2 72
 8 2.142
0.876
-0.185
0.172
1.24
-0.413
1.74
0.996
5.03e-08
NA
0.959
0.146
0.861
0.893
0.0606
1.8
0.992
4.3e-07
NA
HCC38 Buparlisib 3 72
sigmoid
sigmoid
HCC38 buparlisib 0 3 72
 8 1.431
0.674
-0.377
0.272
1.67
-1.0
1.21
0.991
6.94e-07
NA
1.11
0.188
0.824
1.11
0.0
1.32
0.987
2.46e-06
NA
HCC38 BX-912 1 72
sigmoid
sigmoid
HCC38 BX-912 0 1 72
 8 1.760
0.529
-0.322
0.274
0.591
-0.322
4.49
0.999
1.36e-10
NA
0.584
0.149
0.818
0.541
0.149
4.63
0.999
8.39e-10
NA
HCC38 BX-912 2 72
sigmoid
sigmoid
HCC38 BX-912 0 2 72
 8 2.186
0.583
-0.229
0.251
0.648
-0.233
3.62
0.999
9.58e-10
NA
0.602
0.124
0.807
0.559
0.123
3.78
0.998
1.03e-08
NA
HCC38 BX-912 3 72
sigmoid
sigmoid
HCC38 BX-912 0 3 72
 8 1.454
0.422
-0.428
0.365
0.478
-0.433
5.0
0.993
4.02e-07
NA
0.496
0.162
0.778
0.46
0.159
5.0
0.989
1.24e-06
NA
HCC38 Alpelisib 1 72
flat
flat
HCC38 alpelisib 0 1 72
 8 1.738
Inf
0.757
0.0835
0.0
0.757
0.01
0.593
0.0674
0.909
Inf
0.798
0.929
0.0
0.798
0.01
0.579
0.0744
0.923
HCC38 Alpelisib 2 72
flat
flat
HCC38 alpelisib 0 2 72
 8 2.086
Inf
0.848
0.0559
0.0
0.848
0.01
-0.0371
1.0
0.931
Inf
0.848
0.944
0.0
0.848
0.01
-0.0359
1.0
0.932
HCC38 Alpelisib 3 72
flat
flat
HCC38 alpelisib 0 3 72
 8 1.398
Inf
0.75
0.0995
0.0
0.75
0.01
0.141
0.634
0.883
Inf
0.829
0.932
0.0
0.829
0.01
0.113
0.698
0.92
HCC38 CAL-101 1 72
sigmoid
sigmoid
HCC38 idelalisib 0 1 72
 8 1.723
Inf
0.92
0.00328
1.18
0.903
1.47
0.768
0.0125
NA
Inf
0.932
0.997
1.16
0.918
1.48
0.763
0.0133
NA
HCC38 CAL-101 2 72
sigmoid
sigmoid
HCC38 idelalisib 0 2 72
 8 2.154
Inf
0.881
0.0205
0.901
0.879
3.37
0.892
0.00125
NA
Inf
0.876
0.979
0.891
0.874
3.37
0.887
0.00144
NA
HCC38 CAL-101 3 72
sigmoid
sigmoid
HCC38 idelalisib 0 3 72
 8 1.443
Inf
0.851
0.0804
4.08
0.726
0.225
0.706
0.0254
NA
Inf
0.894
0.943
4.27
0.804
0.222
0.707
0.0252
NA
HCC38 Everolimus 1 72
sigmoid
flat
HCC38 everolimus 0 1 72
 8 1.703
11.8
0.54
0.428
0.000126
0.341
0.1
0.688
0.0303
NA
Inf
0.641
0.664
0.0
0.641
0.01
0.571
0.0788
0.665
HCC38 Everolimus 2 72
sigmoid
flat
HCC38 everolimus 0 2 72
 8 2.170
8323.0
0.58
0.376
0.000127
0.417
0.1
0.688
0.0303
NA
Inf
0.6
0.637
0.0
0.6
0.01
0.509
0.119
0.637
HCC38 Everolimus 3 72
sigmoid
sigmoid
HCC38 everolimus 0 3 72
 8 1.437
5.11
0.511
0.429
0.000567
0.299
0.1
0.934
0.000284
NA
573000000.0
0.668
0.707
0.000349
0.53
0.1
0.932
0.000308
NA
HCC38 Pictilisib 1 72
sigmoid
sigmoid
HCC38 pictilisib 0 1 72
 8 1.759
7.16
0.562
0.125
1.04
0.377
0.725
0.992
5.12e-07
NA
Inf
0.647
0.896
0.797
0.529
0.742
0.992
5.77e-07
NA
HCC38 Pictilisib 2 72
sigmoid
sigmoid
HCC38 pictilisib 0 2 72
 8 2.112
Inf
0.622
0.0838
0.644
0.58
1.32
0.933
0.000298
NA
Inf
0.642
0.918
0.568
0.612
1.36
0.922
0.000475
NA
HCC38 Pictilisib 3 72
sigmoid
sigmoid
HCC38 pictilisib 0 3 72
 8 1.420
3.12
0.499
0.129
2.45
0.0818
0.738
0.976
1.33e-05
NA
20.5
0.664
0.911
2.24
0.401
0.731
0.974
1.7e-05
NA
HCC38 GDC-0980 1 72
sigmoid
sigmoid
HCC38 apitolisib 0 1 72
 8 1.777
0.317
0.114
0.305
0.295
0.0315
0.91
0.99
9.47e-07
NA
0.623
0.354
0.761
0.219
0.315
0.951
0.989
1.26e-06
NA